Coupe N, Schadendorf D, Danson S, et al. PACMEL: A randomised phase 2 study of paclitaxel with or without trametinib or pazopanib in Advanced BRAF wild type melanoma. SMR 2017, abstract SMR05-2.
Slechte prognose bij hoogrisico HR+/HER2- borstkanker
aug 2024 | Borstkanker